SCHEMBL1577565

SCHEMBL1577565

CC(=O)Nc1ccc(OCc2ccc(C3CCN(C(=O)O)CC3)cn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
SLC18A3 Q16572 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CCR5 P51681 2/20 0.41
POLB P06746 1/20 0.41
PRMT5 O14744 1/20 0.41
RECQL P46063 1/20 0.40
MCHR1 Q99705 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
DRD2 P14416 1/20 0.40
ADRA1D P25100 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1577838 0.86 NPC1 (0.44) MAPTSMN1; SMN2PRMT5MCHR1
SCHEMBL1577589 0.85 TRPC6 (0.44) MAPTSMN1; SMN2L3MBTL1KMT2ACYP1A2
SCHEMBL1577527 0.82 GPR119 (0.48) PRMT5
SCHEMBL1577998 0.80 CA12 (0.47) KCNH2
SCHEMBL1577844 0.80 LMNA (0.44) MAPTSMN1; SMN2SLC18A3KMT2ALMNA
SCHEMBL1577840 0.80 LMNA (0.44) MAPTSMN1; SMN2SLC18A3KMT2ALMNA
SCHEMBL1577824 0.80 NPY2R (0.42) MAPTSMN1; SMN2L3MBTL1POLBPRMT5
SCHEMBL1952795 0.78 PRMT5 (0.42) MAPTSMN1; SMN2L3MBTL1CYP1A2PRMT5
SCHEMBL1577958 0.78 MEN1 (0.47) MEN1KMT2ACYP1A2PRMT5
SCHEMBL1577822 0.77 GPR119 (0.53) MAPTMEN1KMT2ATDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140018537-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2014-01-16 US disclosed
US-8536176-B2 GPR119 agonist NIPPON CHEMIPHAR CO., LTD. (JP) 2013-09-17 US disclosed
US-20110137032-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2011-06-09 US disclosed
EP-2311822-A1 GPR119 AGONIST Nippon Chemiphar Co., Ltd. (JP) 2011-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018537-A1 GPR119 AGONIST GPR119, GPR27, GPR52 MAPT 4853/4885SMN1; SMN2 3140/4885SLC18A3 943/4885
US-20110137032-A1 GPR119 AGONIST GPR119, GPR27, GPR52 MAPT 4853/4885SMN1; SMN2 3140/4885SLC18A3 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.